Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.11.002
Dong-jue Wei , Hui-juan Li , Zi-pan Lyu , Ai-ping Lyu , Zhao-xiang Bian , Linda LD Zhong
Objective
Functional constipation (FC) is a common intestinal disease worldwide. Despite the presence of criteria such as Roman IV, there is no standardized diagnosis and treatment algorithm in Hong Kong that combines both Western and Chinese medicine approaches. This study integrates current effective and safe diagnosis and treatment methods for FC and provides a clear and scientific pathway for clinical professionals and patients.
Methods
A systematic search of the PubMed, Cochrane Library, and China National Knowledge Infrastructure databases was performed from their inception to June 30th, 2022, collecting the current evidence about the efficacious integrative management for FC. We organized a meeting of professionals in fields relevant to treatment and management of FC to develop a consensus agreement on clinical pathway process.
Results
We developed a clinical pathway for the treatment of FC based on the most recent published guidelines and consultation with experts. This pathway includes a hierarchy of recommendations for every step of the clinical process, including clinical intake, diagnostic examination, recommended labs, diagnostic flowchart, and guidance for selection of therapeutic drugs.
Conclusion
This pathway establishes clinical standards for the diagnosis and treatment of FC using Chinese medicine and Western medicine; it will help to provide high-quality medical services in Hong Kong for patients with FC.
Please cite this article as: Wei DJ, Li HJ, Lyu ZP, Lyu AP, Bian ZX, Zhong LL. A clinical pathway for integrative medicine in the treatment of functional constipation in Hong Kong, China. J Integr Med. 2023; 21(6): 550–560.
{"title":"A clinical pathway for integrative medicine in the treatment of functional constipation in Hong Kong, China","authors":"Dong-jue Wei , Hui-juan Li , Zi-pan Lyu , Ai-ping Lyu , Zhao-xiang Bian , Linda LD Zhong","doi":"10.1016/j.joim.2023.11.002","DOIUrl":"10.1016/j.joim.2023.11.002","url":null,"abstract":"<div><h3>Objective</h3><p><span>Functional constipation (FC) is a common </span>intestinal disease<span><span> worldwide. Despite the presence of criteria such as Roman IV, there is no standardized diagnosis and treatment algorithm in Hong Kong that combines both Western and </span>Chinese medicine approaches. This study integrates current effective and safe diagnosis and treatment methods for FC and provides a clear and scientific pathway for clinical professionals and patients.</span></p></div><div><h3>Methods</h3><p>A systematic search of the PubMed, Cochrane Library, and China National Knowledge Infrastructure databases was performed from their inception to June 30th, 2022, collecting the current evidence about the efficacious integrative management for FC. We organized a meeting of professionals in fields relevant to treatment and management of FC to develop a consensus agreement on clinical pathway process.</p></div><div><h3>Results</h3><p>We developed a clinical pathway for the treatment of FC based on the most recent published guidelines and consultation with experts. This pathway includes a hierarchy of recommendations for every step of the clinical process, including clinical intake, diagnostic examination, recommended labs, diagnostic flowchart, and guidance for selection of therapeutic drugs.</p></div><div><h3>Conclusion</h3><p>This pathway establishes clinical standards for the diagnosis and treatment of FC using Chinese medicine and Western medicine; it will help to provide high-quality medical services in Hong Kong for patients with FC.</p><p><span>Please cite this article as: Wei DJ, Li HJ, Lyu ZP, Lyu AP, Bian ZX, Zhong LL. A clinical pathway for integrative medicine in the treatment of functional constipation in Hong Kong, China. </span><em>J Integr Med</em>. 2023; 21(6): 550–560.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 550-560"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135510212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.10.002
Kang-di Yang, Xu Zhang, Ming-cong Shao, Li-na Wang
Objective
Aconite is a traditional Chinese herbal medicine that has been found to inhibit the development of liver cancer; however, its exact molecular mechanisms in this process remain unclear. This study explores how aconite aqueous extract (AAE) inhibits hepatocellular carcinoma (HCC).
Methods
An in vivo mouse model of subcutaneous liver cancer was established. After AAE treatment, immunohistochemistry (IHC) was used to determine the effect of AAE on natural killer (NK) cells. Subsequently, C57BL/6 mice were used to establish the subcutaneous tumor model, and a group of these mice were treated with anti-PK163 antibody to remove NK cells, which was verified by flow cytometry and IHC. The effect of AAE on the proliferation of HCC cells in vitro was determined using cell counting kit-8. The effect of AAE on chemokine production in HCC cells was measured using real-time quantitative polymerase chain reaction and an enzyme-linked immunosorbent assay. The effect of AAE on the migration of NK cells was determined using a transwell assay. Finally, the molecular mechanism was investigated using the Western blotting method.
Results
We demonstrated that the ability of AAE to induce overexpression of the cytokine C–C motif chemokine ligand 2 (CCL2) in HCC cells is fundamental to the infiltration of NK cells into the tumor bed. Mechanistically, we found that the upregulation of CCL2 was achieved by the activation of c-Jun N-terminal kinase but not extracellular regulated protein kinase or p38.
Conclusion
Our findings suggest that AAE can be used as an effective immune adjuvant to enhance antitumor immunity by increasing NK cell infiltration into tumors, which could help to improve the efficacy of HCC treatments.
Please cite this article as: Yang KD, Zhang X, Shao MC, Wang LN. Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration. J Integr Med. 2023; 21(6): 575–583.
{"title":"Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration","authors":"Kang-di Yang, Xu Zhang, Ming-cong Shao, Li-na Wang","doi":"10.1016/j.joim.2023.10.002","DOIUrl":"10.1016/j.joim.2023.10.002","url":null,"abstract":"<div><h3>Objective</h3><p>Aconite is a traditional Chinese herbal medicine that has been found to inhibit the development of liver cancer; however, its exact molecular mechanisms in this process remain unclear. This study explores how aconite aqueous extract (AAE) inhibits hepatocellular carcinoma (HCC).</p></div><div><h3>Methods</h3><p>An <em>in vivo</em><span><span><span> mouse model of subcutaneous liver cancer was established. After AAE treatment, </span>immunohistochemistry (IHC) was used to determine the effect of AAE on natural killer (NK) cells. Subsequently, C57BL/6 mice were used to establish the subcutaneous tumor model, and a group of these mice were treated with anti-PK163 antibody to remove NK cells, which was verified by flow cytometry and IHC. The effect of AAE on the proliferation of </span>HCC cells </span><em>in vitro</em><span> was determined using cell counting kit-8. The effect of AAE on chemokine<span> production in HCC cells was measured using real-time quantitative polymerase chain reaction and an enzyme-linked immunosorbent assay. The effect of AAE on the migration of NK cells was determined using a transwell assay. Finally, the molecular mechanism was investigated using the Western blotting method.</span></span></p></div><div><h3>Results</h3><p>We demonstrated that the ability of AAE to induce overexpression of the cytokine C–C motif chemokine ligand 2 (CCL2) in HCC cells is fundamental to the infiltration of NK cells into the tumor bed. Mechanistically, we found that the upregulation of CCL2 was achieved by the activation of c-Jun N-terminal kinase but not extracellular regulated protein kinase or p38.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that AAE can be used as an effective immune adjuvant to enhance antitumor immunity by increasing NK cell infiltration into tumors, which could help to improve the efficacy of HCC treatments.</p><p>Please cite this article as: Yang KD, Zhang X, Shao MC, Wang LN. Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration. <em>J Integr Med</em>. 2023; 21(6): 575–583.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 575-583"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92154761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.10.003
Xiao-cong Wang , Xiao-yu Liu , Kang-le Shi , Qing-gang Meng , Yue-fan Yu , Shi-yao Wang , Juan Wang , Chang Qu , Cong Lei , Xin-ping Yu
As one of the key components of clinical trials, blinding, if successfully implemented, can help to mitigate the risks of implementation bias and measurement bias, consequently improving the validity and reliability of the trial results. However, successful blinding in clinical trials of traditional Chinese medicine (TCM) is hard to achieve, and the evaluation of blinding success through blinding assessment lacks established guidelines. Taking into account the challenges associated with blinding in the TCM field, here we present a framework for assessing blinding. Further, this study proposes a blinding assessment protocol for TCM clinical trials, building upon the framework and the existing methods. An assessment report checklist and an approach for evaluating the assessment results are presented based on the proposed protocol. It is anticipated that these improvements to blinding assessment will generate greater awareness among researchers, facilitate the standardization of blinding, and augment the blinding effectiveness. The use of this blinding assessment may further advance the quality and precision of TCM clinical trials and improve the accuracy of the trial results. The blinding assessment protocol will undergo continued optimization and refinement, drawing upon expert consensus and experience derived from clinical trials.
Please cite this article as: Wang XC, Liu XY, Shi KL, Meng QG, Yu YF, Wang SY, Wang J, Qu C, Lei C, Yu XP. Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol. J Integr Med. 2023; 21(6): 528–536.
{"title":"Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol","authors":"Xiao-cong Wang , Xiao-yu Liu , Kang-le Shi , Qing-gang Meng , Yue-fan Yu , Shi-yao Wang , Juan Wang , Chang Qu , Cong Lei , Xin-ping Yu","doi":"10.1016/j.joim.2023.10.003","DOIUrl":"10.1016/j.joim.2023.10.003","url":null,"abstract":"<div><p>As one of the key components of clinical trials<span>, blinding, if successfully implemented, can help to mitigate the risks of implementation bias and measurement bias, consequently improving the validity and reliability of the trial results. However, successful blinding in clinical trials of traditional Chinese medicine (TCM) is hard to achieve, and the evaluation of blinding success through blinding assessment lacks established guidelines. Taking into account the challenges associated with blinding in the TCM field, here we present a framework for assessing blinding. Further, this study proposes a blinding assessment protocol for TCM clinical trials, building upon the framework and the existing methods. An assessment report checklist and an approach for evaluating the assessment results are presented based on the proposed protocol. It is anticipated that these improvements to blinding assessment will generate greater awareness among researchers, facilitate the standardization of blinding, and augment the blinding effectiveness. The use of this blinding assessment may further advance the quality and precision of TCM clinical trials and improve the accuracy of the trial results. The blinding assessment protocol will undergo continued optimization and refinement, drawing upon expert consensus and experience derived from clinical trials.</span></p><p>Please cite this article as: Wang XC, Liu XY, Shi KL, Meng QG, Yu YF, Wang SY, Wang J, Qu C, Lei C, Yu XP. Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol. <em>J Integr Med</em>. 2023; 21(6): 528–536.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 528-536"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92154762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.10.004
Dong Kee Jang , Jun Kyu Lee , Chan Yung Jung , Kyung Ho Kim , Ha Ra Kang , Yeon Sun Lee , Jong Hwa Yoon , Kwang Ro Joo , Min Kyu Chae , Yong Hyeon Baek , Byung-Kwan Seo , Sang Hyub Lee , Chiyeon Lim
Background
Electroacupuncture (EA) may reduce the severity of acute pancreatitis (AP) and provide additional pain relief in patients with chronic pancreatitis. However, the ability of EA to relieve pain in patients with AP has not been well documented.
Objective
This study was undertaken to compare the pain-relieving effects of EA and conventional treatment in patients with AP.
Design, setting, participants and interventions
This study was conducted using a randomized, controlled, three-arm, parallel-group and multi-center design. Patients diagnosed with AP were randomly and equally assigned to EA1, EA2 or control groups. All participants received conventional standard-of-care therapy for AP. Local EA alone was administered in EA1, and local plus distal EA was given in EA2. Local EA included two abdominal acupoints, while distal EA included twelve peripheral acupoints. EA groups underwent one session of EA daily for 4 days (days 1–4), or until pain was resolved or discharged.
Main outcome measures
The primary outcome measure was the change in the visual analogue scale (VAS; 0–100) pain score between baseline and day 5.
Results
Eighty-nine participants were randomized into EA1, EA2 and control groups, and 88 (EA1, 30; EA2, 29; control, 29) were included in the full-analysis set. VAS score change (median [interquartile range]) on day 5 was (12.3 ± 22.5) in the EA1 group, (10.3 ± 21.5) in the EA2 group, and (8.9 ± 15.2) in the control group. There were not significant differences in the change in VAS score among treatments (P = 0.983). However, time to food intake was significantly shorter in the EA group (EA1 + EA2) than in the control group (median 2.0 days vs 3.0 days), with a hazard ratio of 0.581 (P = 0.022; 95% CI, 0.366–0.924). No significant adverse events occurred.
Conclusion
EA treatment did not significantly reduce pain after 4 days of treatment in patients with AP-associated abdominal pain but significantly reduced time to first food intake.
Please cite this article as: Jang DK, Lee JK, Jung CY, Kim KH, Kang HR, Lee YS, Yoon JH, Joo KR, Chae MK, Baek YH, Seo BK, Lee SH, Lim C. Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial. J Integr Med. 2023; 21(6): 537–542.
背景:电针(EA)可以减轻急性胰腺炎(AP)的严重程度,并为慢性胰腺炎患者提供额外的疼痛缓解。然而,EA减轻AP患者疼痛的能力尚未得到很好的证明。目的比较EA治疗与常规治疗对ap患者疼痛的缓解效果。设计、环境、参与者和干预措施本研究采用随机、对照、三臂、平行组和多中心设计。诊断为AP的患者随机平均分配到EA1组、EA2组或对照组。所有参与者均接受常规的AP标准治疗。EA1仅给予局部EA治疗,EA2给予局部加远端EA治疗。局部EA包括2个腹部穴位,远端EA包括12个周围穴位。EA组每日1次,连续4天(第1-4天),或直至疼痛缓解或出院。主要观察指标主要观察指标为视觉模拟量表(VAS;0-100)疼痛评分从基线到第5天。结果89例受试者随机分为EA1组、EA2组和对照组,88例(EA1组,30例;EA2 29;对照组29例,纳入全分析组。第5天,EA1组VAS评分变化(中位数[四分位数范围])为(12.3±22.5)分,EA2组为(10.3±21.5)分,对照组为(8.9±15.2)分。两组间VAS评分变化差异无统计学意义(P = 0.983)。然而,EA组(EA1 + EA2)的进食时间明显短于对照组(中位数为2.0天vs 3.0天),风险比为0.581 (P = 0.022;95% ci, 0.366-0.924)。无明显不良事件发生。结论ea治疗对ap相关性腹痛患者治疗4 d后疼痛无明显缓解作用,但可显著缩短首次进食时间。试验注册:ClinicalTrials.gov标识符NCT03173222。本文题目为:张德奎,李建军,Jung CY, Kim KH, Kang HR, Lee YS, Yoon JH, Joo KR, Chae MK, Baek YH, Seo BK, Lee SH, Lim c。电针缓解急性胰腺炎患者腹痛的三组随机对照试验。中华医学杂志;2009;21(6): 537 - 542。
{"title":"Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial","authors":"Dong Kee Jang , Jun Kyu Lee , Chan Yung Jung , Kyung Ho Kim , Ha Ra Kang , Yeon Sun Lee , Jong Hwa Yoon , Kwang Ro Joo , Min Kyu Chae , Yong Hyeon Baek , Byung-Kwan Seo , Sang Hyub Lee , Chiyeon Lim","doi":"10.1016/j.joim.2023.10.004","DOIUrl":"10.1016/j.joim.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Electroacupuncture<span> (EA) may reduce the severity of acute pancreatitis (AP) and provide additional pain relief in patients<span> with chronic pancreatitis. However, the ability of EA to relieve pain in patients with AP has not been well documented.</span></span></p></div><div><h3>Objective</h3><p>This study was undertaken to compare the pain-relieving effects of EA and conventional treatment in patients with AP.</p></div><div><h3>Design, setting, participants and interventions</h3><p>This study was conducted using a randomized, controlled, three-arm, parallel-group and multi-center design. Patients diagnosed with AP were randomly and equally assigned to EA1, EA2 or control groups. All participants received conventional standard-of-care therapy for AP. Local EA alone was administered in EA1, and local plus distal EA was given in EA2. Local EA included two abdominal acupoints, while distal EA included twelve peripheral acupoints. EA groups underwent one session of EA daily for 4 days (days 1–4), or until pain was resolved or discharged.</p></div><div><h3>Main outcome measures</h3><p>The primary outcome measure was the change in the visual analogue scale (VAS; 0–100) pain score between baseline and day 5.</p></div><div><h3>Results</h3><p>Eighty-nine participants were randomized into EA1, EA2 and control groups, and 88 (EA1, 30; EA2, 29; control, 29) were included in the full-analysis set. VAS score change (median [interquartile range]) on day 5 was (12.3 ± 22.5) in the EA1 group, (10.3 ± 21.5) in the EA2 group, and (8.9 ± 15.2) in the control group. There were not significant differences in the change in VAS score among treatments (<em>P</em> = 0.983). However, time to food intake was significantly shorter in the EA group (EA1 + EA2) than in the control group (median 2.0 days <em>vs</em> 3.0 days), with a hazard ratio of 0.581 (<em>P</em> = 0.022; 95% CI, 0.366–0.924). No significant adverse events occurred.</p></div><div><h3>Conclusion</h3><p>EA treatment did not significantly reduce pain after 4 days of treatment in patients with AP-associated abdominal pain but significantly reduced time to first food intake.</p><p><em>Trial registration:</em> ClinicalTrials.gov identifier NCT03173222.</p><p><span>Please cite this article as: Jang DK, Lee JK, Jung CY, Kim KH, Kang HR, Lee YS, Yoon JH, Joo KR, Chae MK, Baek YH, Seo BK, Lee SH, Lim C. Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial. </span><em>J Integr Med</em>. 2023; 21(6): 537–542.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 537-542"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135325450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.joim.2023.08.003
Ming Huang , Yao-yuan Liu , Ke Xiong , Feng-wen Yang , Xin-yao Jin , Zhao-qi Wang , Jun-hua Zhang , Bo-li Zhang
The global coronavirus disease 2019 (COVID-19) pandemic has had a massive impact on global social and economic development and human health. By combining traditional Chinese medicine (TCM) with modern medicine, the Chinese government has protected public health by supporting all phases of COVID-19 prevention and treatment, including community prevention, clinical treatment, control of disease progression, and promotion of recovery. Modern medicine focuses on viruses, while TCM focuses on differential diagnosis of patterns associated with viral infection of the body and recommends the use of TCM decoctions for differential treatment. This differential diagnosis and treatment approach, with its profoundly empirical nature and holistic view, endows TCM with an accessibility advantage and high application value for dealing with COVID-19. Here, we summarize the advantage of and evidence for TCM use in COVID-19 prevention and treatment to draw attention to the scientific value and accessibility advantage of TCM and to promote the use of TCM in response to public health emergencies.
Please cite this article as: Huang M, Liu YY, Xiong K, Yang FW, Jin XY, Wang ZQ, Zhang JH, Zhang BL. The role and advantage of traditional Chinese medicine in the prevention and treatment of COVID-19. J Integr Med. 2023; 21(5): 407–412.
{"title":"The role and advantage of traditional Chinese medicine in the prevention and treatment of COVID-19","authors":"Ming Huang , Yao-yuan Liu , Ke Xiong , Feng-wen Yang , Xin-yao Jin , Zhao-qi Wang , Jun-hua Zhang , Bo-li Zhang","doi":"10.1016/j.joim.2023.08.003","DOIUrl":"10.1016/j.joim.2023.08.003","url":null,"abstract":"<div><p><span>The global coronavirus disease 2019 (COVID-19) pandemic has had a massive impact on global social and economic development and </span>human health<span>. By combining traditional Chinese medicine<span><span><span> (TCM) with modern medicine, the Chinese government has protected public health by supporting all phases of COVID-19 prevention and treatment<span>, including community prevention, clinical treatment, control of disease progression, and promotion of recovery. Modern medicine focuses on </span></span>viruses, while TCM focuses on differential diagnosis of patterns associated with viral infection of the body and recommends the use of </span>TCM decoctions for differential treatment. This differential diagnosis and treatment approach, with its profoundly empirical nature and holistic view, endows TCM with an accessibility advantage and high application value for dealing with COVID-19. Here, we summarize the advantage of and evidence for TCM use in COVID-19 prevention and treatment to draw attention to the scientific value and accessibility advantage of TCM and to promote the use of TCM in response to public health emergencies.</span></span></p><p>Please cite this article as: Huang M, Liu YY, Xiong K, Yang FW, Jin XY, Wang ZQ, Zhang JH, Zhang BL. The role and advantage of traditional Chinese medicine in the prevention and treatment of COVID-19. <em>J Integr Med</em>. 2023; 21(5): 407–412.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 407-412"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.joim.2023.08.005
Chong-yang Sun , Zhi-yi Xiong , Cheng-yi Sun , Pei-hong Ma , Xiao-yu Liu , Chi-yun Sun , Ze-yin Xin , Bao-yan Liu , Cun-zhi Liu , Shi-yan Yan
Background
The placebo response of sham acupuncture in patients with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.
Objective
This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.
Search strategy
PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.
Inclusion criteria
Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.
Data extraction and analysis
Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.
Results
Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.
Conclusion
Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.
PROSPERO registration number: CRD42022304215.
Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. J Integr Med. 2023; 21(5): 455–463.
背景:假针灸对原发性痛经患者的安慰剂反应是与镇痛相关的一个重要因素。然而,安慰剂反应的程度尚不清楚。目的:本荟萃分析评估了假针灸对原发性痛经患者的疗效及其影响因素。搜索策略:从成立到2022年8月20日,检索PubMed、Embase、Web of Science和Cochrane CENTRAL数据库。纳入标准:随机对照试验(RCT)使用假针灸作为育龄女性原发性痛经患者的对照。数据提取和分析:疼痛强度、回顾性症状量表和健康相关的生活质量是这些试验中使用的结果指标。安慰剂反应被定义为从基线到终点的感兴趣结果的变化。我们使用标准化平均差(SMD)来估计安慰剂反应的影响大小。结果:纳入13项随机对照试验。合并安慰剂对疼痛强度的反应大小最大(SMD=-0.99;95%置信区间[CI],-1.31至-0.68),其次是回顾性症状量表(总频率评分:SMD=-0.20;95%CI,-0.80至-0.39)。平均严重程度评分:SMD=-0.35;95%CI,-0.90至-0.20)和SF-36的物理成分(SMD=0.27;95%CI,-0.17至0.72)。使用钝头针的研究、单中心试验、偏倚风险低的研究、患者病程较长的研究、临床医生的研究结论:原发性痛经患者存在较强的安慰剂反应和一些相关因素。PROSPERO注册号:CRD42022304215。请引用这篇文章:孙,熊,孙,马,刘XY,孙,辛,刘BY,刘CZ,颜SY。假针灸对原发性痛经患者的安慰剂反应:荟萃分析。国际医学杂志,2023;21(5):455-463。
{"title":"Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis","authors":"Chong-yang Sun , Zhi-yi Xiong , Cheng-yi Sun , Pei-hong Ma , Xiao-yu Liu , Chi-yun Sun , Ze-yin Xin , Bao-yan Liu , Cun-zhi Liu , Shi-yan Yan","doi":"10.1016/j.joim.2023.08.005","DOIUrl":"10.1016/j.joim.2023.08.005","url":null,"abstract":"<div><h3>Background</h3><p>The placebo response<span><span> of sham acupuncture </span>in patients<span> with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.</span></span></p></div><div><h3>Objective</h3><p>This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.</p></div><div><h3>Search strategy</h3><p>PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.</p></div><div><h3>Data extraction and analysis</h3><p>Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.</p></div><div><h3>Results</h3><p>Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.</p></div><div><h3>Conclusion</h3><p>Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.</p><p><em>PROSPERO registration number:</em> CRD42022304215.<br></p><p>Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. <em>J Integr Med</em>. 2023; 21(5): 455–463.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 455-463"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.joim.2023.08.004
Mei Zhang , Rui Zheng , Wen-jing Liu , Jun-ling Hou , Yu-lei Yang , Hong-cai Shang
Severe pneumonia is one of the most common infectious diseases and the leading cause of sepsis and septic shock. Preventing infection, balancing the patient’s immune status, and anti-coagulation therapy are all important elements in the treatment of severe pneumonia. As multi-target agents, Xuebijing injection (XBJ) has shown unique advantages in targeting complex conditions and saving the lives of patients with severe pneumonia. This review outlines progress in the understanding of XBJ’s anti-inflammatory, endotoxin antagonism, and anticoagulation effects. From the hundreds of publications released over the past few years, the key results from representative clinical studies of XBJ in the treatment of severe pneumonia were selected and summarized. XBJ was observed to effectively suppress the release of pro-inflammatory cytokines, counter the effects of endotoxin, and assert an anticoagulation effect in most clinical trials, which are consistent with experimental studies. Collectively, this evidence suggests that XBJ could play an important and expanding role in clinical medicine, especially for sepsis, septic shock and severe pneumonia.
Please cite this article as: Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, Shang HC. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives. J Integr Med. 2023; 21(5): 413–422.
{"title":"Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives","authors":"Mei Zhang , Rui Zheng , Wen-jing Liu , Jun-ling Hou , Yu-lei Yang , Hong-cai Shang","doi":"10.1016/j.joim.2023.08.004","DOIUrl":"10.1016/j.joim.2023.08.004","url":null,"abstract":"<div><p><span><span><span>Severe pneumonia is one of the most common infectious diseases and the leading cause of sepsis and septic shock<span>. Preventing infection, balancing the patient’s immune status, and anti-coagulation therapy are all important elements in the treatment of severe pneumonia. As multi-target agents, Xuebijing injection (XBJ) has shown unique advantages in targeting complex conditions and saving the lives of patients with severe pneumonia. This review outlines progress in the understanding of XBJ’s anti-inflammatory, </span></span>endotoxin<span> antagonism, and anticoagulation effects. From the hundreds of publications released over the past few years, the key results from representative clinical studies of XBJ in the treatment of severe pneumonia were selected and summarized. XBJ was observed to effectively suppress the release of pro-inflammatory cytokines, counter the effects of endotoxin, and assert an anticoagulation effect in most </span></span>clinical trials<span>, which are consistent with experimental studies. Collectively, this evidence suggests that XBJ could play an important and expanding role in clinical medicine, especially for sepsis, septic shock and severe pneumonia.</span></span><br></p><p>Please cite this article as: Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, Shang HC. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives. <em>J Integr Med</em>. 2023; 21(5): 413–422.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 413-422"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This work explores the impact of electroacupuncture (EA) on acute postoperative pain (APP) and the role of stimulator of interferon genes/type-1 interferon (STING/IFN-1) signaling pathway modulation in the analgesic effect of EA in APP rats.
Methods
The APP rat model was initiated through abdominal surgery and the animals received two 30 min sessions of EA at bilateral ST36 (Zusanli) and SP6 (Sanyinjiao) acupoints. Mechanical, thermal and cold sensitivity tests were performed to measure the pain threshold, and electroencephalograms were recorded in the primary somatosensory cortex to identify the effects of EA treatment on APP. Western blotting and immunofluorescence were used to examine the expression and distribution of proteins in the STING/IFN-1 pathway as well as neuroinflammation. A STING inhibitor (C-176) was administered intrathecally to verify its role in EA.
Results
APP rats displayed mechanical and thermal hypersensitivities compared to the control group (P < 0.05). APP significantly reduced the amplitude of θ, α and γ oscillations compared to their baseline values (P < 0.05). Interestingly, expression levels of proteins in the STING/IFN-1 pathway were downregulated after inducing APP (P < 0.05). Further, APP increased pro-inflammatory factors, including interleukin-6, tumor necrosis factor-α and inducible nitric oxide synthase, and downregulated anti-inflammatory factors, including interleukin-10 and arginase-1 (P < 0.05). EA effectively attenuated APP-induced painful hypersensitivities (P < 0.05) and restored the θ, α and γ power in APP rats (P < 0.05). Meanwhile, EA distinctly activated the STING/IFN-1 pathway and mitigated the neuroinflammatory response (P < 0.05). Furthermore, STING/IFN-1 was predominantly expressed in isolectin-B4- or calcitonin-gene-related-peptide-labeled dorsal root ganglion neurons and superficial laminae of the spinal dorsal horn. Inhibition of the STING/IFN-1 pathway by intrathecal injection of C-176 weakened the analgesic and anti-inflammatory effects of EA on APP (P < 0.05).
Conclusion
EA can generate robust analgesic and anti-inflammatory effects on APP, and these effects may be linked to activating the STING/IFN-1 pathway, suggesting that STING/IFN-1 may be a target for relieving APP.
Please cite this article as: Ding YY, Xu F, Wang YF, Han LL, Huang SQ, Zhao S, Ma LL, Zhang TH, Zhao WJ, Chen XD. Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway. J Integr Med. 2023; 21(5): 496–508.
{"title":"Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway","authors":"Yuan-yuan Ding , Feng Xu , Ya-feng Wang, Lin-lin Han, Shi-qian Huang, Shuai Zhao, Lu-lin Ma, Tian-hao Zhang, Wen-jing Zhao, Xiang-dong Chen","doi":"10.1016/j.joim.2023.07.001","DOIUrl":"10.1016/j.joim.2023.07.001","url":null,"abstract":"<div><h3>Objective</h3><p><span><span>This work explores the impact of electroacupuncture (EA) on acute </span>postoperative pain (APP) and the role of stimulator of </span>interferon<span><span> genes/type-1 interferon (STING/IFN-1) signaling pathway modulation in the </span>analgesic effect of EA in APP rats.</span></p></div><div><h3>Methods</h3><p>The APP rat model was initiated through abdominal surgery<span><span> and the animals received two 30 min sessions of EA at bilateral ST36 (Zusanli) and SP6 (Sanyinjiao) acupoints. Mechanical, thermal and cold sensitivity tests were performed to measure the pain threshold, and electroencephalograms were recorded in the primary somatosensory cortex to identify the effects of EA </span>treatment<span> on APP. Western blotting<span> and immunofluorescence<span> were used to examine the expression and distribution of proteins in the STING/IFN-1 pathway as well as neuroinflammation. A STING inhibitor (C-176) was administered intrathecally to verify its role in EA.</span></span></span></span></p></div><div><h3>Results</h3><p><span>APP rats displayed mechanical and thermal hypersensitivities compared to the control group (</span><em>P</em> < 0.05). APP significantly reduced the amplitude of θ, α and γ oscillations compared to their baseline values (<em>P</em> < 0.05). Interestingly, expression levels of proteins in the STING/IFN-1 pathway were downregulated after inducing APP (<em>P</em><span> < 0.05). Further, APP increased pro-inflammatory factors, including interleukin-6, tumor necrosis factor-α and inducible nitric oxide synthase, and downregulated anti-inflammatory factors, including interleukin-10 and arginase-1 (</span><em>P</em> < 0.05). EA effectively attenuated APP-induced painful hypersensitivities (<em>P</em> < 0.05) and restored the θ, α and γ power in APP rats (<em>P</em> < 0.05). Meanwhile, EA distinctly activated the STING/IFN-1 pathway and mitigated the neuroinflammatory response (<em>P</em><span><span> < 0.05). Furthermore, STING/IFN-1 was predominantly expressed in isolectin-B4- or calcitonin-gene-related-peptide-labeled dorsal root<span> ganglion neurons and superficial laminae of the spinal dorsal horn. Inhibition of the STING/IFN-1 pathway by </span></span>intrathecal injection<span> of C-176 weakened the analgesic and anti-inflammatory effects of EA on APP (</span></span><em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>EA can generate robust analgesic and anti-inflammatory effects on APP, and these effects may be linked to activating the STING/IFN-1 pathway, suggesting that STING/IFN-1 may be a target for relieving APP.</p><p>Please cite this article as: Ding YY, Xu F, Wang YF, Han LL, Huang SQ, Zhao S, Ma LL, Zhang TH, Zhao WJ, Chen XD. Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway. <em>J Integr Med</em>. 2023; 21(5): 496–508.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 496-508"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10649355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.joim.2023.07.002
Yan-rong Gong , Cheng Zhang , Xing Xiang , Zhi-bo Wang , Yu-qing Wang , Yong-hua Su , Hui-qing Zhang
Objective
This study tests the efficacy of Bletilla striata polysaccharide (BSP), carboxymethyl chitosan (CMC), baicalin (BA) and silver titanate (ST) in a wound dressings to fight infection, promote healing and provide superior biocompatibility.
Methods
The antibacterial activity of BA and ST was evaluated in vitro using the inhibition zone method. BA/ST/BSP/CMC porous sponge dressings were prepared and characterized. The biocompatibility of BA/ST/BSP/CMC was assessed using the cell counting kit-8 assay. The therapeutic effect of BA/ST/BSP/CMC was further investigated using the dorsal skin burn model in Sprague-Dawley rats.
Results
The wound dressing had good antibacterial activity against Escherichia coli and Staphylococcus aureus through BA and ST, while the combination of BSP and CMC played an important role in promoting wound healing. The BA/ST/BSP/CMC porous sponge dressings were prepared using a freeze-drying method with the concentrations of BA and ST at 20 and 0.83 mg/mL, respectively, and the optimal ratio of 5% BSP to 4% CMC was 1:3. The average porosity, water absorption and air permeability of BA/ST/BSP/CMC porous sponge dressings were measured to be 90.43%, 746.1% and 66.60%, respectively. After treatment for 3 and 7 days, the healing rates of the BA/ST/BSP/CMC group and BA/BSP/CMC group were significantly higher than those of the normal saline (NS) group and silver sulfadiazine (SSD) group (P < 0.05). Interleukin-1β expression in the BA/ST/BSP/CMC group at 1 and 3 days was significantly lower than that in the other three groups (P < 0.05). After being treated for 3 days, vascular endothelial growth factor expression in the BA/BSP/CMC group and BA/ST/BSP/CMC group was significantly higher than that in the NS group and SSD group (P < 0.05). Inspection of histological sections showed that the BA/ST/BSP/CMC group and BA/BSP/CMC group began to develop scabbing and peeling of damaged skin after 3 days of treatment, indicating accelerated healing relative to the NS group and SSD group.
Conclusion
The optimized concentration of BA/ST/BSP/CMC dressing was as follows: 6 mg BSP, 14.4 mg CMC, 0.5 mg ST and 12 mg BA. The BA/ST/BSP/CMC dressing, containing antibacterial constituents, was non-cytotoxic and effective in accelerating the healing of burn wounds, making it a promising candidate for wound healing.
Please cite this article as: Gong YR, Zhang C, Xiang X, Wang ZB, Wang YQ, Su YH, Zhang HQ. Baicalin, silver titanate, Bletilla striata polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing. J Integr Med. 2023; 21(5): 487–495.
{"title":"Baicalin, silver titanate, Bletilla striata polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing","authors":"Yan-rong Gong , Cheng Zhang , Xing Xiang , Zhi-bo Wang , Yu-qing Wang , Yong-hua Su , Hui-qing Zhang","doi":"10.1016/j.joim.2023.07.002","DOIUrl":"10.1016/j.joim.2023.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>This study tests the efficacy of <em>Bletilla striata</em><span><span> polysaccharide<span> (BSP), carboxymethyl chitosan (CMC), baicalin (BA) and silver titanate (ST) in a </span></span>wound dressings<span> to fight infection, promote healing and provide superior biocompatibility.</span></span></p></div><div><h3>Methods</h3><p><span>The antibacterial activity of BA and ST was evaluated </span><em>in vitro</em> using the inhibition zone method. BA/ST/BSP/CMC porous sponge dressings were prepared and characterized. The biocompatibility of BA/ST/BSP/CMC was assessed using the cell counting kit-8 assay. The therapeutic effect of BA/ST/BSP/CMC was further investigated using the dorsal skin burn model in Sprague-Dawley rats.</p></div><div><h3>Results</h3><p>The wound dressing had good antibacterial activity against <em>Escherichia coli</em> and <span><em>Staphylococcus aureus</em></span><span> through BA and ST, while the combination of BSP and CMC played an important role in promoting wound healing. The BA/ST/BSP/CMC porous sponge dressings were prepared using a freeze-drying method with the concentrations of BA and ST at 20 and 0.83 mg/mL, respectively, and the optimal ratio of 5% BSP to 4% CMC was 1:3. The average porosity, water absorption and air permeability of BA/ST/BSP/CMC porous sponge dressings were measured to be 90.43%, 746.1% and 66.60%, respectively. After treatment<span> for 3 and 7 days, the healing rates of the BA/ST/BSP/CMC group and BA/BSP/CMC group were significantly higher than those of the normal saline (NS) group and silver sulfadiazine (SSD) group (</span></span><em>P</em> < 0.05). Interleukin-1β expression in the BA/ST/BSP/CMC group at 1 and 3 days was significantly lower than that in the other three groups (<em>P</em> < 0.05). After being treated for 3 days, vascular endothelial growth factor expression in the BA/BSP/CMC group and BA/ST/BSP/CMC group was significantly higher than that in the NS group and SSD group (<em>P</em> < 0.05). Inspection of histological sections showed that the BA/ST/BSP/CMC group and BA/BSP/CMC group began to develop scabbing and peeling of damaged skin after 3 days of treatment, indicating accelerated healing relative to the NS group and SSD group.</p></div><div><h3>Conclusion</h3><p>The optimized concentration of BA/ST/BSP/CMC dressing was as follows: 6 mg BSP, 14.4 mg CMC, 0.5 mg ST and 12 mg BA. The BA/ST/BSP/CMC dressing, containing antibacterial constituents, was non-cytotoxic and effective in accelerating the healing of burn wounds, making it a promising candidate for wound healing.</p><p>Please cite this article as: Gong YR, Zhang C, Xiang X, Wang ZB, Wang YQ, Su YH, Zhang HQ. Baicalin, silver titanate, <em>Bletilla striata</em> polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing. <em>J Integr Med</em>. 2023; 21(5): 487–495.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 487-495"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.joim.2023.06.008
Bing-jie Guo , Yi Ruan , Ya-jing Wang , Chu-lan Xiao , Zhi-peng Zhong , Bin-bin Cheng , Juan Du , Bai Li , Wei Gu , Zi-fei Yin
Objective
Jiedu Recipe (JR), a Chinese herbal remedy, has been shown to prolong overall survival time and decrease recurrence and metastasis rates in patients with hepatocellular carcinoma (HCC). This work investigated the mechanism of JR in HCC treatment.
Methods
The chemical constituents of JR were detected using liquid chromatography-mass spectrometry. The potential anti-HCC mechanism of JR was screened using network pharmacology and messenger ribonucleic acid (mRNA) microarray chip assay, followed by experimental validation in human HCC cells (SMMC-7721 and Huh7) in vitro and a nude mouse subcutaneous transplantation model of HCC in vivo. HCC cell characteristics of proliferation, migration and invasion under hypoxic setting were investigated using thiazolyl blue tetrazolium bromide, wound healing and Transwell assays, respectively. Image-iT™ Hypoxia Reagent was added to reveal hypoxic conditions. Stem cell sphere formation assay was used to detect the stemness. Epithelial-mesenchymal transition (EMT) markers like E-cadherin, vimentin and α-smooth muscle actin, and pluripotent transcription factors including nanog homeobox, octamer-binding transcription factor 4, and sex-determining region Y box protein 2 were analyzed using Western blotting and real-time polymerase chain reaction. Western blot was performed to ascertain the anti-HCC effect of JR under hypoxia involving the Wnt/β-catenin pathway.
Results
According to network pharmacology and mRNA microarray chip analysis, JR may potentially act on hypoxia and inhibit the Wnt/β-catenin pathway. In vitro and in vivo experiments showed that JR significantly decreased hypoxia, and suppressed HCC cell features of proliferation, migration and invasion; furthermore, the hypoxia-induced increases in EMT and stemness marker expression in HCC cells were inhibited by JR. Results based on the co-administration of JR and an agonist (LiCl) or inhibitor (IWR-1-endo) verified that JR suppressed HCC cancer stem-like properties under hypoxia by blocking the Wnt/β-catenin pathway.
Conclusion
JR exerts potent anti-HCC effects by inhibiting cancer stemness via abating the Wnt/β-catenin pathway under hypoxic conditions.
Please cite this article as: Guo BJ, Ruan Y, Wang YJ, Xiao CL, Zhong ZP, Cheng BB, Du J, Li B, Gu W, Yin ZF. Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia. J Integr Med. 2023; 21(5): 474–486.
{"title":"Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia","authors":"Bing-jie Guo , Yi Ruan , Ya-jing Wang , Chu-lan Xiao , Zhi-peng Zhong , Bin-bin Cheng , Juan Du , Bai Li , Wei Gu , Zi-fei Yin","doi":"10.1016/j.joim.2023.06.008","DOIUrl":"10.1016/j.joim.2023.06.008","url":null,"abstract":"<div><h3>Objective</h3><p><span>Jiedu Recipe (JR), a Chinese herbal remedy, has been shown to prolong overall survival time and decrease recurrence and metastasis rates </span>in patients<span> with hepatocellular carcinoma (HCC). This work investigated the mechanism of JR in HCC treatment.</span></p></div><div><h3>Methods</h3><p><span>The chemical constituents of JR were detected using liquid chromatography-mass spectrometry. The potential anti-HCC mechanism of JR was screened using network pharmacology and messenger ribonucleic acid (mRNA) microarray chip assay, followed by experimental validation in human HCC cells (SMMC-7721 and Huh7) </span><em>in vitro</em> and a nude mouse subcutaneous transplantation model of HCC <em>in vivo</em><span>. HCC cell characteristics of proliferation, migration and invasion under hypoxic setting were investigated using thiazolyl blue tetrazolium<span><span> bromide, wound healing and Transwell assays, respectively. Image-iT™ Hypoxia Reagent was added to reveal hypoxic conditions. Stem cell sphere formation assay was used to detect the stemness. Epithelial-mesenchymal transition (EMT) markers like E-cadherin, </span>vimentin<span><span> and α-smooth muscle actin, and pluripotent transcription factors including nanog homeobox, octamer-binding transcription factor 4, and sex-determining region Y box protein 2 were analyzed using </span>Western blotting and real-time polymerase chain reaction. Western blot was performed to ascertain the anti-HCC effect of JR under hypoxia involving the Wnt/β-catenin pathway.</span></span></span></p></div><div><h3>Results</h3><p>According to network pharmacology and mRNA microarray chip analysis, JR may potentially act on hypoxia and inhibit the Wnt/β-catenin pathway. <em>In vitro</em> and <em>in vivo</em> experiments showed that JR significantly decreased hypoxia, and suppressed HCC cell features of proliferation, migration and invasion; furthermore, the hypoxia-induced increases in EMT and stemness marker expression in HCC cells were inhibited by JR. Results based on the co-administration of JR and an agonist (LiCl) or inhibitor (IWR-1-endo) verified that JR suppressed HCC cancer stem-like properties under hypoxia by blocking the Wnt/β-catenin pathway.</p></div><div><h3>Conclusion</h3><p>JR exerts potent anti-HCC effects by inhibiting cancer stemness via abating the Wnt/β-catenin pathway under hypoxic conditions.</p><p><span>Please cite this article as: Guo BJ, Ruan Y, Wang YJ, Xiao CL, Zhong ZP, Cheng BB, Du J, Li B, Gu W, Yin ZF. Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia. </span><em>J Integr Med</em>. 2023; 21(5): 474–486.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 474-486"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}